Efficacy of 5-day parenteral versus intramammary benzylpenicillin for treatment of clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro  by Kalmus, P. et al.
2155
J. Dairy Sci.  97 :2155–2164
http://dx.doi.org/ 10.3168/jds.2013-7338 
© American Dairy Science Association®,  2014 .
 ABSTRACT 
 The efficacy of parenteral (intramuscular) or intra-
mammary (IMM) benzylpenicillin treatment for clinical 
mastitis caused by gram-positive bacteria susceptible to 
penicillin in vitro was investigated. Cows with clinical 
mastitis in 1 udder quarter were randomly placed into 
2 treatment groups. The preliminary bacteriological 
diagnosis of intramammary infection (IMI) was based 
on on-farm culturing, and the bacteriological diagno-
ses were later confirmed by a quantitative PCR assay. 
Clinical mastitis caused by gram-positive bacteria 
susceptible to benzylpenicillin was treated with penicil-
lin via either the parenteral route (20 mg/kg) or IMM 
route (600 mg) once per day for 5 d. The outcome of 
the treatment was evaluated 3 to 4 wk after the onset 
of the treatment. The affected quarter was examined to 
assess the clinical cure, and milk samples were collected 
from the affected quarter to determine the bacteriologi-
cal cure and milk N-acetyl-β-d-glucosaminidase activ-
ity. The survival and the composite milk somatic cell 
counts of the treated cows were followed up for 6 and 
3 mo after treatment, respectively. A total of 140 cows 
with clinical mastitis were included in the study, 61 
being treated with benzylpenicillin parenterally and 79 
via the IMM route. From all quarters treated, 108 of 
140 (77.1%) were cured clinically and 77 of 140 (55.0%) 
were cured bacteriologically. The route of treatment did 
not significantly affect the outcome of the treatment; 
80.3% of the quarters with parenteral treatment and 
74.7% of the quarters with IMM treatment showed a 
clinical cure, and 54.1 and 55.7% a bacteriological cure, 
respectively. The milk N-acetyl-β-d-glucosaminidase 
activity was significantly lower in the quarters with a 
clinical or bacteriological cure than in the quarters with 
no cure. The 6-mo survival and the proportion of cows 
with composite milk somatic cell counts <200,000/mL 
among the treated cows during the 3-mo follow-up pe-
riod did not significantly differ between the treatment 
groups. In conclusion, the outcome of either parenteral 
or IMM benzylpenicillin treatment of clinical mastitis 
caused by penicillin-susceptible bacteria was similar. 
 Key words:   dairy cow ,  clinical mastitis ,  treatment 
route ,  benzylpenicillin 
 INTRODUCTION 
 Bovine mastitis is the most common reason for the 
use of antimicrobials in dairy cows (Thomson et al., 
2008). The most common route of administration for 
the treatment of mastitis is the intramammary (IMM) 
route (Gruet et al., 2001; Ruegg, 2010). Parenteral 
treatment of mastitis has been suggested to be more 
efficient than IMM treatment because of the improved 
distribution of the drug throughout the mammary 
gland (Ziv, 1980; Erskine et al., 2003). This would par-
ticularly apply to invasive infections, such as mastitis 
caused by Staphylococcus aureus (Erskine et al., 2003; 
Smith, 2010). Advantages of the IMM route over the 
parenteral route include high concentrations of the 
substance in the milk (Moretain and Boisseau, 1989; 
Smith, 2010) and lower consumption of the antimicro-
bial, because the dose of the drug directly infused into 
the quarter is small compared with parenteral treat-
ment. A disadvantage of IMM treatment could be an 
uneven distribution of the antimicrobial to the upper 
parts of the affected quarter (Ehinger and Kietzmann, 
2000) and risk for contamination when infusing the 
drug via the teat canal. 
 For the antimicrobial treatment of animal infections, 
such as mastitis, targeting the treatment toward the 
causative agents is recommended (OIE, 2013). If the 
causative agent of infection is susceptible to the so-called 
first-line antimicrobials, such as agents with a relatively 
narrow spectrum, including benzylpenicillin, they 
should be used for treatment (MAFF, 2003; Constable 
et al., 2008). However, in the majority of countries, the 
treatment of mastitis remains reliant on the routine use 
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of combinations of several active substance or broad-
spectrum antimicrobials (Ruegg, 2010). Selection pres-
sure for the development of antimicrobial resistance 
among bacteria is greater when broad-spectrum agents 
are used (Hunter et al., 2010). Parenteral treatment 
with benzylpenicillin has been the treatment of choice 
for clinical mastitis in Nordic countries (Grave et al., 
1999; Thomson et al., 2008; Pyörälä, 2013). Thus far, 
studies comparing the outcome of parenteral and IMM 
treatment of clinical mastitis with benzylpenicillin have 
not been published. One Swedish study compared IMM 
and parenteral penicillin treatment with no treatment 
of subclinical mastitis and the bacteriological cure did 
not differ between the 2 antimicrobial treatment groups 
(Hallén Sandgren et al., 2008).
The gold standard to assess cure after treatment is 
bacteriological culturing, possibly completed with the 
determination of some indicator of inflammation in the 
milk, primarily the milk SCC (Green and Bradley, 2010; 
Ruegg, 2010). Other indicators of inflammation such as 
milk N-acetyl-β-d-glucosaminidase (NAGase) activity 
may also be used (Mattila and Sandholm, 1985). In 
addition, DNA-based bacteriological tests have become 
available for diagnostic use in bovine mastitis, provid-
ing an alternative to conventional culturing, and they 
are also useful for assessing bacteriological cure after 
antimicrobial treatment of mastitis (Koskinen et al., 
2010). The objective of the study was to compare the 
outcome of parenteral and IMM treatment with benzyl-
penicillin in clinical mastitis caused by gram-positive 
bacteria susceptible to penicillin in vitro.
MATERIALS AND METHODS
Characteristics of Study Herds
The study was performed in 4 dairy herds in the 
practice area of the Large Animal Clinic of the Estonian 
University of Life Sciences (Tartu, Estonia) during 2007 
to 2009. The study period was 1 yr in each farm. The 
study was carried out in 2007 in 2 herds, in 2008 in 1 
herd, and in 2009 in 1 herd. The herd size ranged from 
300 to 1,000 dairy cows. All farms were loose-housing 
farms with a side-by-side milking parlor where the cows 
were milked 3 times per day. The average annual milk 
yield was 8,387 kg (minimum = 6,900 kg; maximum = 
9,850 kg). The mean herd bulk milk SCC per month 
ranged between 198,000 and 408,000 cells/mL during 
the study period.
Collection and Analysis of Milk Samples
Any lactating dairy cow with clinical mastitis was 
considered for enrollment in the study. Initial exclusion 
criteria were cows with more than 1 quarter affected 
and cows with known chronic mastitis, defined as cows 
with known high SCC or cows having had more than 
3 mastitis episodes before the beginning of the study. 
Additionally, cows with a visible teat injury, and cows 
treated with antimicrobials within 1 wk before the onset 
of clinical mastitis were excluded. Clinical mastitis was 
defined as any mastitis in which the cow showed vis-
ible, even mild, clinical signs (IDF, 1999). Before treat-
ment, the cow was examined clinically and the results 
recorded on a study form. The clinical signs of the cow 
were assigned to the following 3 categories: (1) mild 
clinical mastitis = changes in the milk appearance, in 
which the milk from the quarter had abnormal viscosity 
(watery or thicker than normal), abnormal color (yel-
low or blood tinged), or abnormal consistency (flakes 
or clots), but no udder swelling or systemic signs; (2) 
moderate clinical mastitis = the same changes in the 
milk appearance and local signs in the quarter, such as 
swelling or pain, but no systemic signs, such as a lack 
of appetite, depressed rumen function, or body tem-
perature greater than 39.2°C; and (3) severe clinical 
mastitis = both local and systemic signs.
Handling of Milk Samples
Clinical examination of the cows, sampling, and on-
farm culturing were done by the local farm veterinar-
ians. Before the study, all veterinarians were trained to 
collect aseptic milk samples and use on-farm culturing 
techniques. An aseptic milk sample was collected from 
the affected quarter before treatment. After discarding 
a few streams of milk, the samples (5–7 mL) were col-
lected into sterile 10-mL plastic tubes. Approximately 
2 mL of milk was separated for preliminary on-farm 
bacteriology and the remaining sample was stored at 
−20°C. All stored milk samples were submitted to the 
Thermo Fisher laboratory for DNA-based diagnosis 
(PathoProof mastitis PCR assay; Thermo Fisher Scien-
tific, Vantaa, Finland) and to the laboratory of the De-
partment of Production Animal Medicine, University 
of Helsinki (Saarentaus, Finland), for determination of 
milk NAGase activity.
Bacteriological Culturing at the Farm
Preliminary bacteriological examination was per-
formed at the farm every evening using Tri-Plate 
selective mastitis agars, including blood-esculin agar, 
mannitol-salt agar, and MacConkey agar (Estonian 
Veterinary and Food Laboratory, Tartu, Estonia). The 
preliminary on-farm bacteriology was used to differenti-
ate between gram-positive and gram-negative bacteria. 
Ten microliters of milk was streaked onto each sec-
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tion and plates were cultured for 12 to 24 h. Bacterial 
growth was evaluated at first on the blood-esculin agar 
and then on the MacConkey agar (the media for detec-
tion of gram-negative bacteria) or on the salt-mannitol 
agar (the medium for detection of staphylococci). 
After detection of staphylococci, penicillin resistance, 
indicated by β-lactamase production, was determined 
using a chromogenic nitrocefin test (Becton Dickinson 
Microbiology Systems, Cockeysville, MD).
Bacteriological Analysis Using  
Real-Time PCR Analysis
Bacteriological diagnosis of mastitis was based on 
the PCR results. A commercial real-time PCR test kit 
(PathoProof mastitis PCR assay; Thermo Fisher Scien-
tific) was used for direct analysis of all milk samples. 
The kit protocol involved 4 separate multiplex real-time 
PCR reactions, which targeted the following bacterial 
species and groups in total: Staphylococcus spp., includ-
ing Staphylococcus aureus and all relevant CNS species; 
Enterococcus spp., including Enterococcus faecalis and 
Enterococcus faecium; Corynebacterium bovis; Esch-
erichia coli; Streptococcus dysgalactiae; Streptococcus 
agalactiae; Streptococcus uberis; Trueperella (formerly 
Arcanobacterium) pyogenes/Peptoniphilus indolicus; 
Klebsiella spp., including Klebsiella oxytoca and Klebsi-
ella pneumoniae; and Serratia marcescens. The PCR as-
say also detected the staphylococcal β-lactamase gene 
blaZ, coding for penicillin resistance. The assay was 
performed according to the manufacturer’s instructions 
and as described by Koskinen et al. (2010). Based on 
the cycle threshold values, the bacterial DNA quantity 
in each targeted bacterial species was grouped into 3 
classes: small (+), intermediate (++), or large (+++) 
quantity.
Milk NAGase Activity Determination
Milk NAGase activity was determined with a fluoro-
optical method using an in-house microplate modifica-
tion (Hovinen et al., 2010) of the method developed 
by Mattila and Sandholm (1985). The calibrated milk 
sample was replaced with a control milk sample with a 
known concentration of 4-methylumbelliferone (4-MU) 
and the NAGase activity was expressed as picomoles of 
4-MU/min per microliter of milk at 25°C. The upper 
detection limit for NAGase activity was 24.49 pmol of 
4-MU/min per microliter. Interassay and intraassay 
coefficients of variation for NAGase activity were 5 and 
4%, respectively.
Treatments
All cows with clinical mastitis were allocated into 
treatment groups A and B using cow ID (A = even 
numbers and B = odd numbers). The following 2 treat-
ments were used: parenteral treatment with benzylpen-
icillin procaine (Penovet; vet 300 mg/mL; Boehringer 
Ingelheim Vetmedica GmbH, Ingelheim, Germany) in 
group A and IMM treatment with benzylpenicillin pro-
caine (Carepen; 600 mg; Vetcare Oy, Salo, Finland) in 
group B. One IMM tube was infused into the affected 
quarter once per day. The dose of benzylpenicillin used 
for parenteral treatment was 20 mg (20,000 IU) per 
kilogram i.m. once per day. The duration of treat-
ment was 5 d in both groups. The use of supportive 
treatment with nonsteroidal antiinflammatory agents 
(NSAID) was possible, but treatment with cortico-
steroids was not allowed. Treatment with penicillin 
according to the defined treatment groups began on 
the day of diagnosis. Treatment was stopped on the 
next day if gram-negative bacteria were detected on 
the selective media or if the isolated staphylococci were 
resistant to penicillin (a positive nitrocefin test). Cases 
of clinical mastitis caused by gram-negative bacteria 
were treated with NSAID, fluid therapy, and if the 
case was severe, with fluoroquinolones. Udder quarters 
infected with penicillin-resistant staphylococci were 
treated with IMM cloxacillin [Wedeclox mastitis; 1,000 
mg of cloxacillin; Wirtschaftsgenossenschaft deutscher 
Tierärzte eG (WDT), Garbsen, Germany] once per day 
for 5 d.
Assessment of Treatment Outcome
The outcome of the treatment was assessed 3 to 4 wk 
after the onset of treatment by using clinical, inflam-
matory, and bacteriological criteria. The milk samples 
were collected as described above and frozen at −20°C. 
The cow was defined as clinically cured if the affected 
quarter was free from clinical signs. A quarter was de-
fined as bacteriologically cured if the DNA of the same 
bacterial species detected in the pretreatment milk 
sample was not present in the follow-up milk sample. A 
quarter with the DNA from the same bacterial species 
detected before the treatment was defined as not cured.
Inflammatory reaction in the affected quarters was 
studied using milk NAGase activity, which should re-
turn back to normal after recovery from inflammation 
(Mattila and Sandholm, 1985). Milk NAGase activity 
was determined in the pretreatment and posttreatment 
milk samples, and used as an additional parameter to 
compare outcomes in the treatment groups (Hovinen et 
al., 2010).
Composite milk SCC (CMSCC) from the cows in-
cluded in the study were collected from the study herds 
once each month during a 3-mo period after the treat-
ment; the mean number of recordings per cow was 2.6. 
The culling data were analyzed during a 6-mo period 
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after the treatment. These data originated from the 
routine herd health recording system.
The Final Enrollment Criteria
Only cows with 1 affected udder quarter (n = 140) 
with penicillin-susceptible, gram-positive bacteria were 
included in the study, based on the following criteria 
regarding the species detected by the PCR assay: (1) 
DNA of 1 bacterial species only, (2) DNA of 1 bacterial 
species in a proportion of over 99% of DNA from all 
target bacterial species detected, or (3) >90% DNA of 
a major pathogen combined with a low quantity (+) of 
DNA of a minor pathogen (CNS or C. bovis).
Polymerase chain reaction-negative samples (n = 25), 
contaminated samples (more than 3 different species 
detected; n = 27), and samples containing DNA from 
gram-negative bacteria (n = 11) were removed from the 
study. Cows (n = 44) treated with IMM cloxacillin, and 
cows (n = 26) with blaZ gene-positive staphylococcal 
species, but treated unintendedly with benzylpenicillin 
were excluded from the main material, but analyzed 
separately.
Statistical Analysis
Prior to the beginning of the study, the sample size 
necessary for statistical evaluation was calculated as 
106 in both treatment groups. The calculations were 
based on the hypothesis that differences in the cure 
rates of the parenteral versus IMM treatment are less 
than 20% (bacteriological cure rates of 65 and 45%, 
respectively; 2-sided P-value at 0.05 and a study power 
of 80%). This hypothesis was based on the assumption 
that a large proportion of cases would be caused by 
Staph. aureus. However, after collection of the data, 
a large proportion of the cows were lost, due to miss-
ing data or post-inclusion exclusions, and the power 
of the study to detect at least a 20% difference in the 
bacteriological cure was 59% (sample size of 61 in the 
parenteral group and 79 in the IMM group).
Logistic regression models were used to evaluate the 
associations between clinical and bacteriological cures 
with treatment route. Bacteriological and clinical cures 
were the outcome variables. The treatment route (IMM 
or parenteral), bacteriological diagnosis as a 7-level 
categorical variable (Staph. aureus, CNS, Strep. aga-
lactiae, Strep. dysgalactiae, Strep. uberis, C. bovis, and 
T. pyogenes), and the continuous variable milk NAGase 
activity in the pretreatment milk samples (as a marker 
of the severity of the inflammation) were included as 
independent variables. Additionally, the lactation num-
ber was used as a 4-level categorical variable (1, 2, 3, 
or ≥4 lactations), the DIM was used as a 4-level cat-
egorized variable (1–30, 31–69, 70–140, or >140 DIM), 
and the farm and affected quarter were used as a 4-level 
variable. Nonsignificant variables were removed using 
a stepwise backward elimination procedure. The Wald 
test was used to evaluate the overall significance of the 
categorical variables with more than 2 levels. No sig-
nificant interactions were detected and as no included 
variables were associated with any outcome variables, 
both final models included only treatment route as in-
dependent variable.
Differences in the number of culled cows between 
the treatment groups during the 6 mo after treatment 
were analyzed with a logistic model in which the treat-
ment, farm, DIM, lactation number, and bacteriologi-
cal diagnosis were included. Variables were categorized 
similarly to the previous models.
A linear regression model was used to investigate 
the associations between milk NAGase activity in the 
posttreatment milk samples and the route of treat-
ment. Before analysis, the outcome variable milk NA-
Gase activity was logarithmically transformed. The 
full models included bacteriological recovery (yes/
no), clinical recovery (yes/no), treatment route, diag-
nosed pathogens, and milk NAGase activity in clinical 
mastitis in the pretreatment milk samples, lactation 
number, DIM, farm, and affected quarter as fixed 
variables. The variables were categorized similarly to 
the previous logistic regression models. The Wald test 
was used to evaluate the overall significance of the 
categorical variables with more than 2 levels. Non-
significant variables were removed using a stepwise 
backward elimination procedure. Possible interaction 
effects of the treatment with diagnosed clinical masti-
tis pathogens, bacteriological cure, clinical cure, and 
farm were verified. No significant interactions were 
detected. Assumptions of the model were controlled 
using normality and scatter plots of the model residu-
als. Stata 11.0 software (StataCorp LP, College Sta-
tion, TX) was used for the logistic regression models 
and linear regression model.
For analyzing associations between the treatment 
and low CMSCC (<200,000 cells/mL) occurrence dur-
ing the 21 to 110 d after the mastitis cases, a gener-
alized linear mixed model was used. For this model, 
PROC GLIMMIX in the SAS/STAT 9.1 software (SAS 
Institute Inc., Cary, NC) was used. An autoregres-
sive correlation structure was used for modeling serial 
correlations of repeated measurements within cows. 
Treatment, time group after mastitis (21–50, 51–80, or 
81–110 d), and their interaction, and sample time in 
relation to mastitis, DIM at the time of mastitis, and 
farm were included as fixed factors.
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RESULTS
Outcome of Benzylpenicillin Treatment
In total, 140 quarters with clinical mastitis were in-
cluded in the study. Clinical signs were defined as mild 
in 83 cows (59.2%) and moderate in 55 cows (39.2%). 
Mastitis was defined as severe in 2 cows (1.4%). Of 140 
quarter cases with clinical mastitis, 61 (43.6%) were 
treated with benzylpenicillin via the parenteral route 
and 79 (56.4%) with benzylpenicillin via the IMM 
route. Distribution of the bacteria detected in the milk 
samples did not significantly differ between the treat-
ment groups (Table 1). Streptococcus uberis was the 
most common bacteriological finding, followed by other 
streptococcal species.
No significant associations between the clinical cure 
[odds ratio (OR) = 1.38; 95% CI: 0.62–3.12; P = 0.43] 
or bacteriological cure (OR = 0.94; 95% CI: 0.48–1.83; 
P = 0.85) and the route of treatment were observed. 
The cure rates for the 140 quarters with clinical mas-
titis infected by gram-positive bacteria susceptible to 
benzylpenicillin in vitro are shown in Table 1.
Milk NAGase activities in the posttreatment samples 
did not differ between the 2 treatment groups (P = 0.69; 
Table 2). Milk NAGase activity was significantly lower 
(P = 0.003) in the quarters with a clinical cure than 
the quarters with no clinical cure and in the bacterio-
logically cured quarters compared with those without 
bacteriological cure (P = 0.002; Table 2). The median 
NAGase activities in the milk before treatment and in 
the posttreatment samples are presented in Table 3.
In total, the number of culled cows was 18 (13.1%) by 
the end of the 6-mo follow-up period after treatment. 
No data were available for 3 cows. No significant differ-
ences between the treatment groups (OR = 0.91; 95% 
CI: 0.33–2.46; P = 0.51) were found.
CMSCC After Treatment
Individual-cow CMSCC data from 3 routine test 
milkings (every 30 d) during the 3-mo follow-up period 
after treatment were available for 126 cows. The sum-
mary of data and the proportion of cows with CMSCC 
<200,000 cells/mL in the 2 treatment groups at differ-
ent time points after treatment is shown in Table 4. No 
association (P = 0.79) between the route of penicillin 
treatment and the proportion of cows with CMSCC 
<200,000/mL after treatment was seen.
DISCUSSION
In this study, the outcome of benzylpenicillin treat-
ment of clinical mastitis caused by gram-positive bac-
teria susceptible to penicillin in vitro was not affected 
by the route of administration of the drug. Clinical 
studies comparing the efficacy of parenteral and IMM 
treatment for clinical mastitis are, in general, rare. 
To our knowledge, field trials comparing the efficacy 
of parenteral and IMM benzylpenicillin treatment of 
bovine clinical mastitis have not been published. 
Parenteral penethamate hydroiodide treatment was 
compared with IMM penicillin-dihydrostreptomycin 
treatment in a study performed in New Zealand, and 
no significant differences were observed (McDougall, 
1998). The majority of mastitis cases in that study 
were caused by Strep. uberis, a species susceptible to 
benzylpenicillin. Sérieys et al. (2005) compared treat-
ment with parenteral penethamate to IMM ampicillin-
cloxacillin, with no significant differences between the 
2 treatment regimens. Specific information regarding 
the in vitro susceptibility of the causative agents was 
not available, and no real comparison can be made. 
In clinical mastitis experimentally induced by Strep. 
uberis and treated with penicillin, bacteriological cure 
Table 1. The outcome of parenteral and intramammary 5-d treatment with benzylpenicillin of bovine clinical mastitis (n = 140 quarters) caused 
by gram-positive bacteria susceptible to benzylpenicillin in vitro 
Pathogen









Staphylococcus aureus (n = 8) 1/2 5/6 1/2 5/6
CNS (n = 13) 4/6 6/7 2/6 4/7
Streptococcus uberis (n = 66) 29/34 22/32 20/34 16/32
Streptococcus agalactiae (n = 14) 6/6 6/8 4/6 6/8
Streptococcus dysgalactiae (n = 19) 5/8 9/11 5/8 8/11
Corynebacterium bovis (n = 6) 1/1 3/5 0/1 3/5
Trueperella pyogenes/Peptoniphilus indolicus (n = 14) 3/4 8/10 1/4 2/10
Total (n = 140)3 (% in parentheses) 49/61 (80.3) 59/79 (74.7) 33/61 (54.1) 44/79 (55.7)
1Intramuscular treatment.
2Intramammary treatment.
3The proportion of cured udder quarters.
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did not differ between IMM, parenteral, or combined 
treatment groups; however, the groups were so small 
that no conclusions could be made (Hillerton and 
Kliem, 2002). The dose of benzylpenicillin procaine 
used in that study was half of that used in our study, 
which could affect the parenteral cure rates. No dif-
ferences between parenteral benzylpenicillin and IMM 
penethamate were found for the treatment of subclini-
cal mastitis caused by penicillin-sensitive Staph. aureus 
or streptococci (Hallén Sandgren et al., 2008). In an 
old US study, the efficacy of IMM amoxicillin alone 
or combined with intramuscular benzylpenicillin was 
compared for the treatment of subclinical Staph. aureus 
mastitis (Owens et al., 1988). Bacteriological cure rates 
were approximately 50% and did not differ between the 
treatments; however, because no information regard-
ing penicillin susceptibility was available, drawing any 
conclusions is difficult.
Overall, the bacteriological cure rates of clinical mas-
titis caused by staphylococci and streptococci treated 
with different antimicrobials and routes of administra-
tion have ranged from 56 to 84% (Jarp et al., 1989; 
Taponen et al., 2003a; Sérieys et al., 2005; McDougall 
et al., 2007; Apparao et al., 2009; Bradley and Green, 
2009; Ruegg, 2010). Taponen et al. (2003a) used a 
4-d treatment with IMM benzylpenicillin for mastitis 
caused by penicillin-susceptible, gram-positive bacteria 
and reported a clinical cure rate of 75% and a bacterio-
logical cure rate of 73%. The clinical cure rate was simi-
lar to our study, but the bacteriological cure rate was 
approximately 20% higher than in the present study, 
which may be due to the different clinical severity of 
Table 2. Linear regression model of associations between milk N-acetyl-β-d-glucosaminidase (NAGase) 
activity in the posttreatment milk sample (n = 140) and route (intramammary or parenteral) of treatment in 
clinical mastitis caused by gram-positive bacteria 
Variable Estimate1 95% CI P-value
Wald test  
(P-value)
Treatment2
 IMM (n = 79) 0
 i.m. (n = 61) −0.08 −0.44 to 0.26 0.69
Bacteriological cure
 No (n = 63) 0
 Yes (n = 77) −0.58 −0.95 to −0.21 0.002
Clinical cure
 No (n = 32) 0
 Yes (n = 108) −0.67 −1.11 to −0.23 0.003
Farm 0.00
 Farm 1 (n = 17) 0
 Farm 2 (n = 11) −0.28 −1.12 to 0.55 0.51
 Farm 3 (n = 66) −1.01 −1.67 to −0.47 0.001
 Farm 4 (n = 46) −0.13 −0.81 to 0.43 0.54
Intercept 2.532 1.851 to 3.213 0.00
1Estimates are on a logarithmic scale.
2IMM = intramammary treatment; i.m. = intramuscular treatment.
Table 3. Milk N-acetyl-β-d-glucosaminidase (NAGase) activity in milk samples from quarters with clinical or 
bacteriological cure or no cure (n = 140) before and after 5-d parenteral or intramammary penicillin treatment 
of clinical mastitis caused by gram-positive bacteria 
Item
Median milk NAGase activity  
(pmol of 4-MU/min per microliter)1
Before treatment After treatment
Clinical cure
 Yes (n = 108) 24.18 (0.53; 24.49) 2.73 (0.75; 24.29)
 No (n = 32) 17.17 (1.49; 24.49) 5.84 (0.59; 24.49)
Bacteriological cure
 Yes (n = 77) 17.58 (1.49; 24.49) 2.44 (0.15; 24.49)
 No (n = 63) 24.49 (0.53; 24.49) 3.41 (0.16; 24.49)
Treatment2
 i.m. (n = 61) 24.49 (1.22; 24.49) 2.32 (0.15; 24.49)
 IMM (n = 79) 20.53 (0.53; 24.49) 3.12 (0.16; 24.49)
14-MU = 4-methylumbelliferone. Minimum and maximum values are shown in parentheses.
2i.m. = intramuscular treatment; IMM = intramammary treatment.
Journal of Dairy Science Vol. 97 No. 4, 2014
TREATMENT OF CLINICAL MASTITIS 2161
mastitis or different methods used for the bacteriologi-
cal follow-up. Jarp et al. (1989) reported a total bacte-
riological cure rate of 68% for clinical mastitis due to 
gram-positive, penicillin-susceptible bacteria, treated 
for 5 d with benzylpenicillin, using the same dose as 
in the current study. The cure rate of that study was 
also higher than reported in our study, possibly due to 
the same reasons as mentioned earlier. Bacteriological 
cure rates of mastitis depend on the causative agent. 
McDougall et al. (2007) compared treatment of clinical 
mastitis with 3 different IMM products, one of them 
containing procaine penicillin alone. More than half of 
the cases were caused by Strep. uberis and treatment 
with penicillin IMM for 1.5 d resulted in a cure rate 
as high as 91%, which is much higher than found here. 
Different conditions in the New Zealand, such as much 
lower average milk production and less severe clinical 
signs, may at least partly explain the difference.
Mastitis-causing streptococcal species have remained 
susceptible to benzylpenicillin (Pitkälä et al., 2004; Hen-
driksen et al., 2008; Bengtsson et al., 2009; Kalmus et 
al., 2011). Staphylococcus aureus and CNS isolated from 
bovine mastitis have developed resistance to penicillin 
(Hendriksen et al., 2008; Bagcigil et al., 2012), which 
may significantly influence the efficacy of treatment 
(Pyörälä and Pyörälä 1998; Sol et al.; 2000; Taponen et 
al., 2003b). In our study, 6 of 8 cases of mastitis caused 
by penicillin-susceptible Staph. aureus were cured using 
either intramuscular or IMM penicillin treatment. The 
bacteriological cure of 20 quarters with mastitis caused 
by penicillin-resistant Staph. aureus treated for 5 d 
with cloxacillin was in the present study zero (data not 
shown). It is known that mastitis caused by penicillin-
resistant Staph. aureus is difficult to cure (Taponen et 
al., 2003b; Barkema et al., 2006). The poor treatment 
response of these cases is mainly not derived from 
antibiotic resistance. The ability of penicillin-resistant 
Staph. aureus isolates to cause persistent infections may 
be due to several virulence factors, possibly linked to 
the β-lactamase gene of the resistant isolates (Haveri et 
al., 2005; van den Borne et al., 2010). In the treatment 
of mastitis, tested or assumed in vitro susceptibility of 
the causing bacteria is considered a prerequisite for the 
use of a particular antibiotic, but pretreatment suscep-
tibility is not always predictive of treatment response 
in vivo (Barlow, 2011).
Benzylpenicillin is a weak acid, which, after paren-
teral administration, penetrates poorly into the mam-
mary gland. However, because the minimum inhibitory 
concentration values for susceptible organisms are gen-
erally very low (≤0.12 μg/mL for staphylococci and 
≤0.06 μg/mL for streptococci; Prescott, 2007; Bengts-
son et al., 2009), it is possible to achieve and maintain 
therapeutic concentrations in the milk using parenteral 
administration of 20 mg of benzylpenicillin procaine/kg 
once per day as used in the current study (Franklin et 
al., 1984; Ziv and Storper, 1985).
Intramammary infusion results in concentrations as 
high as 100- to 1,000-fold of those obtained with par-
enteral administration, which is advantageous for infec-
tions of the milk compartment, such as streptococcal 
mastitis (Moretain and Boisseau, 1989; Erskine et al., 
2003). The total dose of antimicrobials administered 
via the IMM route is considerably lower than that in 
parenteral treatment. Furthermore, painful injections 
can be avoided. When infusing IMM containing nar-
row-spectrum antimicrobials antibiotics such as ben-
zylpenicillin, strict hygienic measures should be used 
to avoid inducing mastitis (Middleton and Luby, 2008). 
Intramammary administration is the route of choice for 
mastitis caused by streptococcal species, which reside in 
the milk compartment (Erskine et al., 2003). Parenteral 
or combined treatment has been suggested for mastitis 
caused by Staph. aureus (Erskine et al., 2003; Constable 
et al., 2008). Taponen et al. (2003b) reported a bacte-
riological cure of 72% for mastitis caused by penicillin-
susceptible Staph. aureus treated with 5-d combined 
parenteral and IMM treatment with penicillin. In our 
Table 4. Individual-cow composite milk SCC (CMSCC) and proportions of cows with CMSCC <200,000 cells/mL collected during a 3-mo 
period (21–110 d) after parenteral or intramammary penicillin treatment of clinical mastitis caused by gram-positive bacteria 
Period (d) after  
clinical mastitis  
and treatment1
Individual cow CMSCC (cells/mL) Proportion of samples  
with CMSCC below  
200,000 cells/mL (%) P-valueMean (±SD) Median (minimum; maximum)
21–50 d 0.14
 i.m. (n = 59) 456,400 (±649,800) 194,000 (17,000; 3,287,000) 50.8
 IMM (n = 70) 851,246 (±1,332,200) 260,000 (5,000; 7,073,000) 39.6
51–80 d 0.31
 i.m. (n = 49) 408,604 (±526,540) 210,000 (11,000; 2,384,000) 47.4
 IMM (n = 62) 678,700 (±1,392,500) 1,818,000 (9,000; 6,565,000) 56.8
81–110 d 0.46
 i.m. (n = 46) 670,100 (±1,175,300) 256,500 (8,000; 6,062,000) 43.2
 IMM (n = 53) 648,900 (±1,251,200) 195,000 (10,000; 8,272,000) 50.6
1i.m. = intramuscular treatment; IMM = intramammary treatment.
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study, no difference was observed between the 2 routes 
of treatment, but the Staph. aureus group was too small 
to draw any conclusions. Our group infected with CNS 
was also small, but based on the literature, IMM is 
the route of choice in the treatment of CNS mastitis 
(Erskine et al., 2003; Pyörälä and Taponen, 2009).
In this study, bacteriological diagnosis was based on 
a PCR assay. For the evaluation of the bacteriologi-
cal cure, strict criteria were used. If DNA of the same 
species detected before treatment was found alone or 
together with the DNA of other species in the post-
treatment sample, the case was classified as not cured. 
It is known that the PCR-based assay is more sensitive 
than conventional culture (Koskinen et al., 2010). This 
may be reflected as lower percentages of cure than in 
previous studies in which conventional culturing was 
used for assessment. Excluding all samples with more 
than 1 species from the analysis would result in the dis-
carding of a considerable number of cases, because the 
PCR test often detects more than 1 species (Koskinen 
et al., 2010).
Higher cure rates may have also been expected here 
because our 5-d treatment was longer than standard 
treatments used for mastitis in many countries. Lon-
ger treatments have been reported to result in higher 
cure rates, at least for mastitis caused by Staph. aureus 
and Strep. uberis (Jarp et al., 1989; Oliver et al., 2004; 
Deluyker et al., 2005; Krömker et al., 2010). Recently, 
5-d treatment with cefquinome did not increase cure 
rates in clinical Staph. aureus mastitis compared with 
1.5-d treatment (Swinkels et al., 2013). This discrepant 
result may be due to the drug used or differences in the 
virulence of the bacterial strains causing IMI.
In assessing cure rates, the possibility of contamina-
tion of the sample with the same species as detected in 
the pretreatment sample should also to be taken into 
account. This could lead to a false-positive sample and 
false classification of the case as not cured. However, 
this affects both conventional and PCR-based tests. If 
PCR assays are used to assess the outcome in treat-
ment trials of mastitis, some adjustments to the tests 
may be necessary for the interpretation of results.
Combining bacteriology with some indicator of in-
flammation in the milk would be useful for confirming 
the assessment (Green and Bradley, 2010). The most 
common indicator used to monitor the inflammatory 
status of the udder is milk SCC. Milk NAGase activity 
is another good choice for this purpose (Pyörälä, 2003). 
N-Acetyl-β-d-glucosaminidase originates from somatic 
cells but also from damaged epithelial cells (Mattila 
and Sandholm, 1985; Pyörälä, 2003). It correlates well 
with milk SCC and has the advantage that freezing 
the milk samples does not interfere with the analysis 
(Pyörälä, 2003). The threshold values of these param-
eters should perhaps be adjusted for the assessment of 
the response to mastitis treatment, because the inflam-
matory reaction of the quarter may last longer than 
elimination of the infection. The threshold levels of the 
markers used for screening of mastitis may be too high 
for monitoring the recovery of the quarter (Pyörälä and 
Pyörälä, 1997).
Generally, 2 posttreatment samples are recommended 
for the bacteriological evaluation of cure (Schukken and 
Deluyker, 1995). Here, only 1 sample was collected for 
practical reasons, but we used a sensitive PCR assay 
for bacteriology, which could somewhat compensate 
for the lack of the second sampling. Including the cow 
survival data and cow composite milk SCC follow-up 
provides information regarding the long-term effects of 
the treatments and can be recommended for field trials 
of mastitis. In the present study, the CMSCC remained 
higher and the proportion of low-CMSCC cows was 
numerically smaller in the IMM-treated group, even 
though no significant differences between the groups 
were found. A possible explanation for this result is 
that the cows had other quarters with subclinical IMI, 
which were also treated when the treatment was ad-
ministered parenterally and this may have affected cow 
CMSCC.
CONCLUSIONS
The outcome of parenteral or IMM penicillin treat-
ment of mastitis caused by penicillin-susceptible bac-
teria was found to be similar. We conclude that IMM 
could routinely be used for the treatment of clinical 
mastitis caused by streptococcal species. Streptococci 
reside in the milk compartment and no pharmacoki-
netic grounds exist for the use of parenteral administra-
tion of the antimicrobial. Parenteral treatment is more 
invasive and significantly increases the dose of the anti-
microbial. The number of quarters infected with Staph. 
aureus was too low to reach any conclusions regarding 
treatment of Staph. aureus mastitis. With a more sensi-
tive PCR method, bacteriological cure rates may be 
lower, which should be considered by researchers, the 
pharmaceutical industry, and authorities in the future.
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